<unk>  is an monoclonal antibody that is FDA approved for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) and also indicated for the treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, and pyrexia..
Ibritumomab tiuxetan
Tositumomab
Axitinib
Fostamatinib
Neratinib
Dasatinib
Afatinib
Dabrafenib mesylate